Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor
DeannaLee M. Beauvais(University of Wisconsin–Madison), Alan C. Rapraeger(University of Wisconsin–Madison)
Cited by 278
Related Papers
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins
|Oncogenesis|2016|111
Interaction of Syndecan and α6β4 Integrin Cytoplasmic Domains
|Journal of Biological Chemistry|2010|67
Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface
|Frontiers in Oncology|2021|18
Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression
|Journal of Biological Chemistry|2022|10
SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression
|Signal Transduction and Targeted Therapy|2026|0